Article Sidebar

PDF
Date Published: 23/09/2022
Abstract Views: 420
Views PDF: 259
DOI: https://doi.org/10.51298/vmj.v518i1.3313
Issue
Vol. 518 No. 1 (2022)
Section
Các bài báo
How to Cite
Thị Hoa, N. ., Thị Huyền, P. ., Thị Yến, L. ., Thị Hòa, N. ., & Thị Hồng Nhật, Đoàn . (2022). RESULTS OF ADJUVANT CHEMOTHERAPY DOCETAXEL - CARBOPLATIN – TRASTUZUMAB REGIMEN IN HER2/NEU POSITIVE BREAST CANCER PATIENTS. Vietnam Medical Journal, 518(1). https://doi.org/10.51298/vmj.v518i1.3313

RESULTS OF ADJUVANT CHEMOTHERAPY DOCETAXEL - CARBOPLATIN – TRASTUZUMAB REGIMEN IN HER2/NEU POSITIVE BREAST CANCER PATIENTS

Nguyễn Thị Hoa1,, Phùng Thị Huyền2, Lê Thị Yến2, Nguyễn Thị Hòa2, Đoàn Thị Hồng Nhật3
1 Hung Vuong General Hospital, Phu Tho Province
2 Vietnam National Cancer Hospital
3 Vinh Medical University

Main Article Content

Abstract

Objectives: To evaluate the efficacy of adjuvant chemotherapy Docetaxel – Carboplatin – Trastuzumab regimen in Her2/neu positive breast cancer patients. Subjects and methods: A descriptive cohort study was conducted on 51 patients with stage I – II – IIIA breast cancer (BC) after radical mastectomy or conservative surgery with systemic axillary lymph node dissection received adjuvant chemotherapy Docetaxel – Carboplatin – Trastuzumab regimen at K hospital from January 2014 to the end of May 2021, and followed up until the end of May 2022. Results: The most common age group in our study is 60 – 70 years old, accounting for 49.0%; 45.1% of patients had stage I. The majority of patients received modified radical mastectomy, accounting for 90.2%. Patients with adjuvant radiation therapy accounted for 43.1%; 23.5% of patients received adjuvant AI treatment. Adjuvant Tamoxifen accounted was administered in 15.7% patients. Median disease free survival was 71.0 (95%CI: 60.7 – 81.3) months. The rate of neutropenia is 43.1%; in which grade 3 – 4 neutropenia accounted for 17.6%; the rate of neutropenia with fever is 11.8%; There were no cases of anemia or thrombocytopenia grade 3 – 4; The rate of EF reduction > 16% was 0.5%. Conclusion: Adjuvant chemotherapy Docetaxel – Carboplatin – Trastuzumab regimen has good efficacy in prolonging disease free survival time as well as low toxicity for breast cancer patients.

Article Details

Keywords

BC (breast cancer)

References

1. Trần Văn Thuấn (2011), Điều trị nội khoa bệnh ung thư vú, Nhà xuất bản Y học, Hà Nội.
2. GLOBOCAN 2020: New Global Cancer Data | UICC. , accessed: 05/07/2022.
3. Hudis C.A. (2007). Trastuzumab mechanism of action and use in clinical practice. N Engl J Med, 357(1), 39–51.
4. Suter T.M., Procter M., van Veldhuisen D.J et al. (2007). Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol, 25(25), 3859–3865.
5. Slamon D., Eiermann W., Robert N. et al. (2011). Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine, 365(14), 1273–1283.
6. Slamon D., Eiermann W., Robert N. et al. (2016). Abstract S5-04: Ten years follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer.
7. Wu D. và Xiong L. (2020). Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER‑2‑positive breast cancer patients. Oncology Letters, 19(3), 2539–2546.
8. Bayo J., Aviñó V., Toscano F. et al. (2018). Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis. Breast J, 24(4), 462–467.